Sofinnova Partners’ Post

𝗡𝗲𝘅𝘁-𝗴𝗲𝗻 𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗮𝗰𝗰𝗲𝘀𝘀 𝗶𝘀 𝗼𝗻 𝘁𝗵𝗲 𝗵𝗼𝗿𝗶𝘇𝗼𝗻!🌅 Venova Medical, Inc. Medical secured a US$30 million Series B funding round, co-led by CHV (Catalyst Health Ventures) and a leading medical device company, alongside notable investors like ShangBay Capital, Mirae Asset Capital, KOFA Healthcare, Cadence Healthcare Ventures, and Aphelion Capital. This is a significant milestone that will undoubtedly propel the development of their groundbreaking Velocity pAVF System. The Velocity pAVF System represents a transformative leap in hemodialysis access, offering a minimally invasive solution for creating arteriovenous fistulas (AVFs). This innovative technology is designed to provide optimal and durable fistula flow, ensuring safer, more effective, and longer-lasting vascular access for patients undergoing dialysis. In the words of CEO Erik van der Burg, "We believe that the Velocity pAVF System will become the new standard of care, reducing barriers and improving outcomes for patients starting dialysis." The addition of Darshana Zaveri to Venova’s board of directors is another exciting development. Her expertise will be invaluable as Venova Medical continues its journey towards FDA approval and market expansion. This milestone marks a critical step forward in improving the quality of life for patients with kidney failure. Here's to the continued success of Venova Medical in revolutionizing vascular access for hemodialysis! #MedicalDevices #Hemodialysis #VascularAccess #VenovaMedical #SeriesB #PatientCare

Big news in Medtech! Merit Medical just made a bold $105M move, scooping up the EsophyX Z+ device from EndoGastric Solutions. This isn't just a win for Merit; it's a game-changer for those battling GERD. This smart addition is all about minimally invasive treatment, offering fresh hope and cutting-edge care without a single incision. With Merit Medical's focus on strategic growth, this deal isn't merely a purchase; it's a leap forward expanding their reach in gastrointestinal care. Thoughts on how this acquisition might change the playing field? Drop your take below! #Medtech #Innovation #HealthcareIndustry

💰 Edwards Lifesciences to acquire Innovalve Bio Medical Ltd. Combined with Edwards Lifesciences’ existing mitral innovations, the acquisition enhances the company’s TMVR technologies to address large unmet structural heart patient needs and support sustainable long-term growth. Innovalve Bio Medical Ltd. will join the transcatheter mitral and tricuspid therapies (TMTT) product group, led by corporate vice president, Daveen Chopra. Edwards Lifesciences is developing a portfolio of transcatheter repair and replacement therapies designed to address mitral and tricuspid valve diseases. Read more online: https://lnkd.in/geN-TSZc 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

Lithotripsy provides an important treatment option in dealing with some of the most difficult to treat vascular lesions-namely those that are heavily calcified and resistant to stand dilation and stenting. The interest in strategics in pursuing companies with a solution for that problem is logical and expected. As other options to Shockwave emerge such as Amplitude Vasculat Systems, the interest in those technologies will grow as well. Finding the most effective and least traumatic strategy for treating such lesions with lithotripsy should provide the greatest appeal

🌟 Amazing Deal Alert! 🌟 Johnson & Johnson is making waves in the Cardiac Disease MedTech market with their $1.1 billion acquisition of V-Wave. A significant move by a major player, setting their footprint even deeper into this critical area of healthcare. 🔍 One key aspect to note: the regulatory milestones embedded in this deal. It's a reminder of just how crucial a strong regulatory strategy is—it's literally worth gold! 💰 If you want to ensure your company is on the right path and maximize investor confidence, let’s have a quick chat to see how we can develop a winning regulatory strategy for you. #MedTech #CardiacHealth #RegulatoryStrategy #HealthcareInnovation #JohnsonAndJohnson #Investment #HealthTech #AR2C2 https://lnkd.in/g397KUQG

Orthofix Reports Second Quarter 2024 Results and Raises Full-Year 2024 Financial Guidance LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2024 and increased its full-year 2024 financial guidance. Recent Highlights Second quarter 2024 net sales of $198.6 million, an increase of 6% on a reported and constant currency basis compared to second quarter 2023 Bone Growth Therapies (BGT) net sales growth of 12% compared to second quarter 2023, marking six consecutive quarters with double-digit via Business Wire Health: Medical Devices News

MedTech Strategist is honored to welcome CorInnova, Inc. alongside President & CEO William Altman as a Presenting Company at the 10th Annual Innovation Summit Dublin 2024. Presenting in the Cardiovascular and Mechanical Circulatory Support Therapeutic Categories, CorInnova (Texas Medical Center, Houston, Texas USA) has developed a revolutionary device for the treatment of heart failure promising to double the $5B market for short-term cardiac assist (< 5 days’ use) by treating the 50% of patients unable to use existing devices, including more women who receive only 25% of cardiac devices. The pneumatically driven device surrounds both ventricles and does not touch the blood, avoiding many blood-related adverse events. Air inflates the device synchronously with the heart, gently squeezing the heart for increased output and recovery. Welcome to #InnovationDublin24, William and CorInnova, Inc.! Celebrate 10 years of Innovation Summit in Dublin, Ireland April 16-18, 2024. Request to register to attend now: https://bit.ly/48M8npY #medtech #medicaldevices #medtechinnovation #heartfailure #cardiacassistance #devices

⛔ 𝐈𝐬 𝐌𝐃𝐑/𝐈𝐕𝐃𝐑 𝐭𝐫𝐚𝐧𝐬𝐢𝐭𝐢𝐨𝐧 𝐩𝐮𝐭𝐭𝐢𝐧𝐠 𝐲𝐨𝐮𝐫 𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐝𝐞𝐯𝐢𝐜𝐞 𝐚𝐭 𝐫𝐢𝐬𝐤 𝐨𝐟 𝐝𝐢𝐬𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐢𝐭𝐲? Recent surveys - find the links in the comment section of this post - show the reality for many medical device manufacturers: compliance costs and bureaucratic challenges are causing 53% 𝐨𝐟 𝐩𝐫𝐨𝐝𝐮𝐜𝐭 𝐫𝐚𝐧𝐠𝐞𝐬 𝐭𝐨 𝐟𝐚𝐜𝐞 𝐩𝐚𝐫𝐭𝐢𝐚𝐥 𝐨𝐫 𝐟𝐮𝐥𝐥 𝐝𝐢𝐬𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐭𝐡𝐞 𝐄𝐔, 𝐰𝐡𝐢𝐥𝐞 91% 𝐨𝐟 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐜𝐢𝐭𝐞 𝐌𝐃𝐑/𝐈𝐕𝐃𝐑 𝐚𝐧𝐝 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐜𝐞𝐫𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐞𝐱𝐩𝐞𝐧𝐬𝐞𝐬 𝐚𝐬 𝐚 𝐩𝐫𝐢𝐦𝐚𝐫𝐲 𝐫𝐞𝐚𝐬𝐨𝐧, underscoring the financial burden these new regulations impose. At 𝐎𝐋𝐊𝐎𝐍, we’re committed to 𝐦𝐚𝐤𝐢𝐧𝐠 𝐚𝐧 𝐢𝐦𝐩𝐚𝐜𝐭 𝐭𝐡𝐞 𝐫𝐢𝐠𝐡𝐭 𝐰𝐚𝐲, thus helping to ensure clinical continuity. 🏥 To ease these burdens, we offer a 25% 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭💡 on consulting services to support your compliance efforts for already MDD/IVDD compliant devices - from  QMS implementation and regulatory compliance consulting to supporting clinical evaluations and investigations. We are also open to exploring flexible financing options with distributors, manufacturers, or insurance partners to help you keep your devices available and compliant. 𝐖𝐡𝐚𝐭 𝐝𝐨 𝐲𝐨𝐮 𝐭𝐡𝐢𝐧𝐤 𝐚𝐛𝐨𝐮𝐭 𝐨𝐮𝐫 𝐢𝐧𝐢𝐭𝐢𝐚𝐭𝐢𝐯𝐞? 🤔 Ambu A/S, Fischer Medical KLS Martin Group, Teleflex, Convatec, Nobel Biocare, Koch Medical GmbH & Co. KG, Merit Medical EMEA, Mindray, BD, Dräger, QURA Srl, Endologix LLC, Elos Medtech, Hemex Health, Inc., Mediso Medical Imaging Systems, 77 Elektronika Ltd., FEMTONICS, MedTech Europe, BVMed - Bundesverband Medizintechnologie, Medtronic, Johnson & Johnson MedTech, Roche Diagnostics France, Siemens Healthineers, GE HealthCare, Abbott, Phillips Healthcare, Ortho Baltic, Stryker, Zimmer Biomet, Fresenius Medical Care, Elos Medtech, BIOTRONIK, STAAR Surgical, Micrel Medical Devices, Regenity Biosciences (Formerly Polyganics), Esaote, Medartis, RaySearch Laboratories #Healthcare #MedicalDevices #MDR #IVDR #ClinicalContinuity #RegulatoryCompliance

Sozinibercept (OPT-302) has the potential to redefine the treatment landscape for wet AMD. This innovative treatment aims to address the still unmet medical need for improved visual outcomes. In this recent interview we speak with Opthea CEO Frederic Guerard, PharmD, MS; Opthea Chief Medical Advisor Arshad Khanani, MD, MA, FASRS; Charles C. Wykoff, MD, PhD, FASRS, FACS; and Veeral S. Sheth, MD, MBA, FASRS, FACS, about the potential of sozinibercept to become the first therapy with a novel mechanism of action targeting superior efficacy compared to standard of care in over 15 vears. https://bit.ly/3KE8uJK #sponsored

Qsight Alpha Expands its Offering with Model for AFib Market Investors keen on medical technology advancements will find this data invaluable. The newest addition to Qsight Alpha’s Medical Device coverage is a multi-company model that is focused on the different cardiac ablation devices used in the treatment of Atrial Fibrillation (AFib). Get granular insight on market share across the various companies, methods of ablation, and key products in addition to the sales estimates Qsight Alpha has built its reputation on. With what will be a major area of interest in 2024, track the progress of the breakthrough Pulse Field Ablation (PFA) products that are being launched this year by Abbott (ABT), Boston Scientific (BSX), Johnson & Johnson (JNJ), and Medtronic (MDT). To empower your decision-making with critical insights from Qsight Alpha, schedule a demo now: https://lnkd.in/ekEzm4Uu #PredictiveAnalytics #MarketInsights #BusinessForecasting #QsightAlpha